| scholarly article | Q13442814 |
| P356 | DOI | 10.1001/JAMA.1995.03520310033026 |
| P5875 | ResearchGate publication ID | 236312052 |
| P2093 | author name string | Donna Shattuck-Eidens | |
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ovarian cancer | Q172341 |
| collaboration | Q1145523 | ||
| P304 | page(s) | 535 | |
| P577 | publication date | 1995-02-15 | |
| P1433 | published in | The Journal of the American Medical Association | Q1470970 |
| P1476 | title | A Collaborative Survey of 80 Mutations in the BRCA1 Breast and Ovarian Cancer Susceptibility Gene | |
| P478 | volume | 273 |
| Q41526204 | A Review of Hereditary Breast Cancer: From Screening to Risk Factor Modification |
| Q28271567 | A canine model of familial mammary gland neoplasia |
| Q53638062 | A common BRCA1 mutation in the Ashkenazim. |
| Q38459569 | A founder mutation of the BRCA1 gene in Western Sweden associated with a high incidence of breast and ovarian cancer |
| Q60074873 | A human BRCA1 gene knockout |
| Q30471451 | A novel BRCA1 mutation in an identical twin pair with similar clinical histories |
| Q43615414 | A real-time characterization method to rapidly optimize molecular beacon signal for sensitive nucleic acids analysis |
| Q48074726 | A somatic BRCA1 mutation in an ovarian tumour |
| Q52036972 | Analysis of mutational spectra: locating hotspots and clusters of mutations using recursive segmentation. |
| Q26851594 | Arginine methyltransferases as novel therapeutic targets for breast cancer |
| Q28302118 | Association of BRCA1 with Rad51 in mitotic and meiotic cells |
| Q85527285 | BRCA1 Testing: Genetic Counseling Protocol Development and Counseling Issues |
| Q35160913 | BRCA1 alterations are associated with endometriosis, but BRCA2 alterations show no detectable endometriosis risk: a study in Indian population. |
| Q33644841 | BRCA1 and BRCA2 gene mutations and risk of breast cancer. Public health perspectives |
| Q24650826 | BRCA1 and BRCA2 mutations in Scotland and Northern Ireland |
| Q74449532 | BRCA1 and BRCA2 mutations in Turkish familial and non-familial ovarian cancer patients: a high incidence of mutations in non-familial cases |
| Q37149848 | BRCA1 and BRCA2: different roles in a common pathway of genome protection |
| Q34444787 | BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients |
| Q59312570 | BRCA1 mutation analysis in 83 Spanish breast and breast/ovarian cancer families |
| Q73351867 | BRCA1 mutation testing for Japanese patients with ovarian cancer in breast cancer screening |
| Q36617295 | BRCA1 mutations and other sequence variants in a population-based sample of Australian women with breast cancer |
| Q38474993 | BRCA1 mutations found in archived early onset breast tumours |
| Q53004441 | BRCA1 mutations in German breast-cancer families. |
| Q57250773 | BRCA1 mutations in young women with breast cancer |
| Q74525381 | BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing |
| Q72345825 | BRCA1: more than a hereditary breast cancer gene? |
| Q34732377 | Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities |
| Q44602623 | Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations |
| Q50692482 | Breast and ovarian cancer screening practices in healthy women with a strong family history of breast or ovarian cancer. |
| Q34098601 | Breast cancer in women < or = 35 years: review of 1002 cases from a single institution. |
| Q37011738 | Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations |
| Q40415946 | Breast cancer: cause and prevention |
| Q57838458 | Characterisation of the BRCT Domains of the Breast Cancer Susceptibility Gene Product BRCA1 |
| Q43730286 | Clinical and genetic evaluation of thirty ovarian cancer families. |
| Q56438399 | Combined loss of BRCA1/BRCA2 in grade 3 breast carcinomas |
| Q37885224 | Common BRCA1 and BRCA2 mutations in breast cancer families: a meta-analysis from systematic review |
| Q40907038 | Controlled trial of pretest education approaches to enhance informed decision-making for BRCA1 gene testing. |
| Q34729086 | Counseling the at risk patient in the BRCA1 and BRCA2 Era. |
| Q40598619 | Cytoplasmic mislocalization of BRCA1 caused by cancer-associated mutations in the BRCT domain. |
| Q40919883 | Detection of heterozygous mutations in BRCA1 using high density oligonucleotide arrays and two-colour fluorescence analysis |
| Q47577422 | Detection of protein folding defects caused by BRCA1-BRCT truncation and missense mutations |
| Q53673657 | Effects of a web-based intervention on women's breast health behaviors. |
| Q71511813 | Estimating disease risks for individuals with a given family history in different populations with an application to breast cancer |
| Q73066469 | Family history of breast and ovarian cancer and the risk of breast carcinoma in situ |
| Q74460330 | Functional analysis of CpG methylation in the BRCA1 promoter region |
| Q59081423 | Further enigmatic variations |
| Q24803349 | Future possibilities in the prevention of breast cancer: intervention strategies in BRCA1 and BRCA2 mutation carriers |
| Q33915583 | Genes implicated in hereditary breast cancer syndromes |
| Q33836065 | Genetic predisposition to breast cancer: a surgical perspective |
| Q33595704 | Genetic susceptibility testing and prophylactic oophorectomy |
| Q35552631 | Genetics and the Management of Women at High Risk for Breast Cancer |
| Q34175539 | Germ line mutations associated with breast cancer susceptibility |
| Q71107825 | Germline BRCA1 185delAG mutations in Jewish women with breast cancer |
| Q57266937 | Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype–phenotype correlation |
| Q72046532 | High allele loss rates at 17q12-q21 in breast and ovarian tumors from BRCAl-linked families. The Breast Cancer Linkage Consortium |
| Q73093633 | Homonucleotide tracts, short repeats and CpG/CpNpG motifs are frequent sites for heterogeneous mutations in the neurofibromatosis type 1 (NF1) tumour-suppressor gene |
| Q41615934 | Human ovarian cancer of the surface epithelium |
| Q73404724 | Immunohistochemically detected p53 and HER-2/neu expression and nuclear DNA content in familial epithelial ovarian carcinomas |
| Q44180684 | Is hereditary site-specific ovarian cancer a distinct genetic condition? |
| Q48045595 | Localization of BRCA1 gene expression in adult cynomolgus monkey tissues |
| Q24308016 | Localization of BRCA1 protein in breast cancer tissue and cell lines with mutations |
| Q34492521 | Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas |
| Q73333881 | MALDI-TOF based mutation detection using tagged in vitro synthesized peptides |
| Q33813990 | Managing hereditary ovarian cancer risk |
| Q38221583 | Multiple primary cancers as a guide to heritability |
| Q55243800 | Multiplex mutation screening of the BRCA1 gene in 1000 Japanese breast cancers. |
| Q54787853 | Mutational screening of breast cancer susceptibility gene 1 from early onset, bi-lateral, and familial breast cancer patients in Taiwan. |
| Q71532382 | Mutations and polymorphisms in the familial early-onset breast cancer (BRCA1) gene. Breast Cancer Information Core |
| Q41457953 | Mutations of the BRCA1 and BRCA2 genes and the possibilities for predictive testing |
| Q28204191 | Novel consensus DNA‐binding sequence for BRCA1 protein complexes |
| Q24796354 | Novel mutations in the BRCA1 and BRCA2 genes in Iranian women with early-onset breast cancer |
| Q59548827 | Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus |
| Q36619469 | Ovarian cysts in women receiving tamoxifen for breast cancer |
| Q77441926 | Pathobiologic characteristics of hereditary breast cancer |
| Q41441051 | Predisposition testing for breast and ovarian cancer susceptibility |
| Q43360167 | Prevention in the year 2002: some news, some issues |
| Q35108378 | Principles of cancer screening. |
| Q62978349 | Rapid detection of BRCA1 mutations by the protein truncation test |
| Q73551538 | Reproductive factors in hereditary breast cancer |
| Q47770236 | Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations |
| Q71676992 | Risk assessment and presymptomatic molecular diagnosis in hereditary breast cancer |
| Q71721150 | Risk assessment and religion |
| Q33859275 | Screening for hereditary cancer and genetic testing, epitomized by breast cancer. |
| Q55176423 | Screening of BRCA1 mutation using immunohistochemical staining with C-terminal and N-terminal antibodies in familial ovarian cancers. |
| Q54417578 | Somatic mutations in the BRCA1 gene in sporadic ovarian tumours. |
| Q78171497 | Some genetic aspects of ovarian tumors |
| Q36695832 | The BOADICEA model of genetic susceptibility to breast and ovarian cancer |
| Q28282486 | The C-terminal (BRCT) domains of BRCA1 interact in vivo with CtIP, a protein implicated in the CtBP pathway of transcriptional repression |
| Q85527256 | The Familial Cancer Program of the Vermont Cancer Center: Development of a Cancer Genetics Program in a Rural Area |
| Q41584547 | The Human Genome Project and breast cancer |
| Q24292058 | The LIM domain protein LMO4 interacts with the cofactor CtIP and the tumor suppressor BRCA1 and inhibits BRCA1 activity |
| Q34294785 | The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals |
| Q41226231 | The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds |
| Q26851138 | The expanding role of yeast in cancer research and diagnosis: insights into the function of the oncosuppressors p53 and BRCA1/2 |
| Q41625163 | Tumor suppressor genes and human cancer |
| Q73347724 | Tumour biological features of BRCA1-induced breast and ovarian cancer |
| Q73294051 | Utility of linked markers in genetic counseling: estimation of carrier risks in X-linked ocular albinism |
Search more.